Abstract
Since their proposal in 1976, sigma (σ) receptors have been increasingly implicated in the pathophysiology of virtually all major central nervous system (CNS) disorders, including anxiety, depression, schizophrenia, and drug addiction. Due to their involvement in motor function and higher cognitive function,σ receptors have also been implicated in movement disorders (such as Parkinson's disease) and memory deficits (including Alzheimer's disease). In most cases the precise mechanism(s) linking σ receptors to CNS disease are unknown or yet to be fully elucidated. However, many σ ligands have shown promise in pharmacological studies and animal models of the aforementioned diseases, and some have entered clinical trials. This review will assess the validity of σ receptors as a target for various CNS diseases based on evidence from animal models of human diseases, preclinical studies in humans, and full clinical trials.
Keywords: Sigma receptor, central nervous system, schizophrenia, anxiety, depression, Alzheimer's disease, addiction, pain, clinical trials, tumor cells
Current Pharmaceutical Design
Title: The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Volume: 18 Issue: 7
Author(s): Samuel D. Banister and Michael Kassiou
Affiliation:
Keywords: Sigma receptor, central nervous system, schizophrenia, anxiety, depression, Alzheimer's disease, addiction, pain, clinical trials, tumor cells
Abstract: Since their proposal in 1976, sigma (σ) receptors have been increasingly implicated in the pathophysiology of virtually all major central nervous system (CNS) disorders, including anxiety, depression, schizophrenia, and drug addiction. Due to their involvement in motor function and higher cognitive function,σ receptors have also been implicated in movement disorders (such as Parkinson's disease) and memory deficits (including Alzheimer's disease). In most cases the precise mechanism(s) linking σ receptors to CNS disease are unknown or yet to be fully elucidated. However, many σ ligands have shown promise in pharmacological studies and animal models of the aforementioned diseases, and some have entered clinical trials. This review will assess the validity of σ receptors as a target for various CNS diseases based on evidence from animal models of human diseases, preclinical studies in humans, and full clinical trials.
Export Options
About this article
Cite this article as:
D. Banister Samuel and Kassiou Michael, The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436539
DOI https://dx.doi.org/10.2174/138161212799436539 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Carbohydrates and Epithelial Repair - More Than Just Post-Translational Modification
Current Drug Targets Ventricular Arrhythmias in Patients with Obstructive Sleep Apnea
Current Cardiology Reviews Pharmacological Aspects of (-)-Deprenyl
Current Medicinal Chemistry Critical Role of Computer Simulations in Drug Discovery and Development
Current Topics in Medicinal Chemistry Current Understanding of Dyslexia and Pilot Data on Efficacy of a Mindfulness Based Psychotherapy (MBR-RAM) Model
Adolescent Psychiatry Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery
Current Neuropharmacology Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design Headache in Multiple Sclerosis - Pharmacological Aspects
Current Pharmaceutical Design Synthetic Pulmonary Surfactant Preparations: New Developments and Future Trends
Current Medicinal Chemistry Drug Design Benefits from Molecular Dynamics: Some Examples
Current Computer-Aided Drug Design 3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity
Medicinal Chemistry A Study of Tryptophan Metabolism via Serotonin in Ventricular Cerebrospinal Fluid in HIV-1 Infection Using a Neuroendoscopic Technique
Current HIV Research Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Protein Misfolding in Disease and Small Molecule Therapies
Current Topics in Medicinal Chemistry Metabolomic Approach in Probing Drug Candidates
Current Topics in Medicinal Chemistry Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Molecular Chaperones as Rational Drug Targets for Parkinsons Disease Therapeutics
CNS & Neurological Disorders - Drug Targets Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry